Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 35, Issue SUPPL. 4, 2002, Pages

  Tolia, Vasundhara ^a   Ferry, George ^b   Gunasekaran, Thirumazhisai ^c   Huang, Bidan ^d   Keith, Roberta ^e   Book, Linda ^f  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c Lutheran General Children's Hospital   (United States)

^d ABBOTT LABORATORIES   (United States)

^e TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^f UNIVERSITY OF UTAH   (United States)

Author keywords

Children; Esophagitis; Gastroesophageal reflux disease; Lansoprazole

Indexed keywords

ANTACID AGENT; CHILDRENS MYLANTA; LANSOPRAZOLE;

ABDOMINAL PAIN; ARTICLE; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HEMATEMESIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; PH MEASUREMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SYMPTOMATOLOGY; VOMITING; WHEEZING;

EID: 0036445689     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200211004-00003     Document Type: Article

References (45)

1. Shaw MJ, Adlis SA, Beebe TJ. When does simple heartburn become a disease [Abstract]. Gastroenterology 1998;114:A284.
2. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted Country, Minnesota. Gastroenterology 1997;112:1448-56.
3. Callahan CW. The diagnosis of gastroesophageal reflux in hospitalized infants: 1971-1995. J Am Osteopath Assoc 1998;98:32-4.
4. Nelson SP, Chen EH, Syniar GM, Christoffel KK, for the Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med 2000;154:150-4.
5. Orenstein SR. Gastroesophageal reflux. Curr Prob Pediatr 1991;May/June:193-241.
6. Werlin SL, Dodds WJ, Hogan WJ, Arndorfer RC. Mechanisms of gastroesophageal reflux in children. J Pediatr 1980;97:244-9.
7. Richter JE, Castell DO. Chest pain of esophageal origin. Dig Dis 1989;7:39-50.
8. Richter JE. Estraesophageal presentations of gastroesophageal reflux disease. Semin Gastrointest Dis 1997;8:75-89.
9. DeMeester TR, O'Sullivan GC, Bermudez G, et al. Esophageal function in patients with angina-type chest pain and normal coronary angiograms. Ann Surg 1982;196:488-98.
10. Koufman JA. Lipoinjection for vocal cord paralysis. Laryngoscope 1991;101:1385.
11. Euler AR, Ament ME. Value of esophageal manometric studies in the gastroesophageal reflux of infancy. Pediatrics 1977;59:58.
12. Herbst JJ, Book LS, Bray PF. Gastroesophageal reflux in the "near miss" sudden infant death syndrome. J Pediatr 1978:92:73-5.
13. Johnsson F, Joelsson B, Gudmundsson K, et al. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987;22:714-718.
14. Spechler SJ. Epidemiology and natural history of gastrooesophageal reflux disease. Digestion 1992;51(suppl 1):24-9.
15. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
16. Robinson M, Earnest D, Rodriquez- Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998;158:2373-6.
17. Sontag SJ, Kugut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997;92:429-37.
18. Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The lansoprazole maintenance study group. Am J Gastroenterol 1996;91:1758-65.
19. Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:859-67.
20. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996;10:529-39.
21. Earnest DL, Dorsch E, Jones J, et al. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998;93:238-43.
22. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IV (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996;8:1101-6.
23. Carling L, Axelsson CK, Forssell H, et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: A long-term comparative study. Aliment Pharmacol Ther 1998;12:985-90.
24. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996;91:1749-57.
25. Blum RA, Shi H, Karol MD. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997;19:1013-23.
26. Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997;11:541-6.
27. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-1810.
28. Huang J-Q, Hunt RH. Meta-analysis of comparative trials for healing erosive esophagitis (EE) with proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) [abstract]. Gastroenterology 1998;114:A154.
29. Robinson M, Campbell DR, Sontag S, Sabesin SM. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995;40:590-7.
30. Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: Pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol 2002;35(supp 4):S327-35.
31. Gremse D, Winter H, Tolia V, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol 2002;35(supp 4):S319-26.
32. Tolia V, Fitzgerald J, Hassall E, Huang B, Pilmer B, Kane R. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol 2002;35(supp 4):S300-7.
33. Scott Levin & Associates. IMS America Prescription Audit. Scott Levin Audit 2000.
34. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. Am J Gastroenterol 1974;62:325-32.
35. Dekkers CP, Beker JA, Thjodeleifsson B, et al. Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999;13:49-57.
36. Corinaldesi R, Valentini M, Belaiche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicenter study. Aliment Pharmacol Ther 1995;9:667-71.
37. Huang JQ, Sridhar S, Hunt RH. Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors (PPIs)? A meta-analysis of comparative trials. [abstract] Gut 1999; 45:P513.
38. Tolia V. Indications for proton pump inhibitors in pediatrics. Paediatrics Today 2001;IV:180-6.
39. Gunasekaran TS, Hassall E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-54.
40. Israel DM, Hassall E. Omeprazole and other proton pump inhibitors: Pharmacology, efficacy and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998;27:568-79.
41. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000;137:800-7.
42. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32:660-6.
43. Faure C, Michaud L, Khan Shaghaghi E, et al. Lansoprazole in children: Pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1397-402.
44. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TOG, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: Results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001;96:3089-98.
45. Richter JE, Kovacs TOG, Greski-Rose PA, Huang B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive esophagitis. Aliment Pharmacol Ther 1999;13:795-804.